T-cell Therapy Market Overview:

According to IMARC Group latest report titled “T-cell Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a comprehensive analysis of the industry, which comprises insights on . The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global T-cell therapy market is expected to exhibit a CAGR of 16.9% during 2022-2027.

T-cell therapy refers to an immunotherapy approach, which is also known as adoptive cell transfer (ACT), wherein the immune cells from the body of the patient are used to treat cancer. It comprises of an antigen-binding domain (ectodomain), a transmembrane domain, intracellular (endodomain), and Immune Receptor Tyrosine-Based Activation Motifs (ITAMs). T-cell therapy can be based on CAR T-cells, T-cell Receptors (TCRs), or Tumor-Infiltrating Lymphocytes (TIL). It involves collecting T-cells via apheresis and re-engineering them in a laboratory. These re-engineered cells are multiplied and then infused into the body to recognize and kill cancer cells with targeted antigens on their surface. As a result, T-cell therapy is widely utilized in cancer treatment centers and hospitals across the globe.

Request to Get the Free Sample Report: https://www.imarcgroup.com/t-cell-therapy-market/requestsample

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Market Trends:

The growing incidences of cancer, owing to the escalating consumption of tobacco products, unhealthy food habits, and sedentary lifestyles, are primarily driving the T-cell therapy market. In line with this, the increasing prevalence of bone marrow and blood-forming tissue diseases is further catalyzing the market growth. Moreover, the sudden outbreak of the COVID-19 pandemic is propelling the adoption of T-cell therapies for nursing high-risk patients, which is also augmenting the global market. Besides this, the expanding utilization of ACT processes for treating children with Acute Lymphoblastic Leukemia (ALL) and adults with advanced lymphomas is projected to bolster the T-cell therapy market over the forecasted period.

Competitive Landscape with Key players:

The report has also analysed the competitive landscape of the market with some of the key players being.

• Amgen Inc.
• Aurora Biopharma Inc.
• bluebird bio Inc
• Bristol-Myers Squibb Company
• Fate Therapeutics
• Gilead Sciences Inc.
• Merck KGaA
• Mustang Bio Inc.
• Novartis AG
• Pfizer Inc.
• Sorrento Therapeutics Inc.
• TCR2 Therapeutics

T-cell Therapy Market Segmentation:

Our report has categorized the market based on region, modality, therapy type and indication.

Modality:

• Research
• Commercialized

Therapy Type:

• CAR T-cell based
• T Cell Receptor (TCR) based
• Tumor Infiltrating Lymphocytes (TIL) based

Indication:

• Hematologic Malignancies
• Lymphoma
• Leukemia
• Myeloma
• Solid Tumors
• Melanoma
• Brain and Central Nervous System
• Liver Cancer
• Others
• Others

Market Breakup by Region:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:

• Market Performance (2016-2021)
• Market Outlook (2022-2027)
• Porter’s Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

We are updating our reports, If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Competitive landscape, etc. Click request free sample report, the report will be delivered to you in PDF format via email within 24 to 48 hours after the payment confirmation.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800